Cannabis Cuts TMD Jaw Pain by 90% in New Clinical Trial

A clinical trial published in the journal Clinics has delivered one of the most striking pain-relief signals yet in the 2026 medical cannabis research wave. In adults with chronic temporomandibular disorder (TMD), sublingual cannabis extracts containing a balanced ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD) cut average pain scores nearly in half and dropped functional pain — pain triggered by jaw movement — by roughly 90 percent. Mouth opening improved measurably, and hallmark symptoms such as allodynia and hyperalgesia were nearly eliminated by the end of treatment.

The TMD finding lands at a moment when clinicians, payers, and patients are reassessing how cannabinoids fit into chronic-pain protocols, particularly for conditions that respond poorly to traditional analgesics. It is also part of a broader 2026 picture in which more than 100 peer-reviewed cannabis studies have been published in the first five months of the year, with growing attention to functional outcomes rather than just self-reported relief.

What TMD Is and Why It Resists Standard Treatment

Temporomandibular disorder is an umbrella term for chronic conditions affecting the jaw joint and the muscles that control it. Symptoms include persistent jaw pain, clicking or locking of the joint, headaches, ear pain, and limited mouth opening. Myofascial TMD — pain originating from the chewing muscles themselves — is particularly common and particularly stubborn.

Standard treatment combines physical therapy, occlusal splints, nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and in some cases injections. Many patients improve, but a significant minority continue to live with daily pain, sleep disruption, and difficulty eating. For that group, the search for non-opioid options has been a clinical priority for years.

How the 2026 Study Was Designed

Brazilian researchers ran a prospective crossover trial comparing sublingual cannabis extracts against a placebo in 20 adults with chronic myofascial TMD. The study design used each participant as their own control: every patient received placebo for 90 days, followed by 90 days of cannabis extract under a slow up-titration protocol.

The cannabis protocol started low. Participants began at 2 milligrams per day in week one, then increased by 2 milligrams per week until reaching 10 milligrams per day in week five. Dosing was sublingual, allowing the cannabinoids to be absorbed through the tissues under the tongue rather than swallowed and metabolized first by the liver. The extracts contained balanced amounts of THC and CBD, the most-studied pair in modern cannabis pharmacology.

Outcome measurement was both subjective and functional. The team tracked self-reported pain on a standard 0-to-10 numerical rating scale, but also measured maximum mouth opening, sensitivity to touch and pressure (allodynia and hyperalgesia), and pain triggered by jaw movement.

The Pain Results: 7.35 to 3.50 on the Scale

The headline number from the trial is the change in average pain. Across the cannabis treatment phase, mean pain scores fell from 7.35 to 3.50 on the 10-point scale — a roughly 52 percent reduction. For chronic pain populations, a change of that magnitude is rare in any single intervention and tends to clear the threshold patients describe as a meaningful improvement in daily life.

The functional-pain finding was even more dramatic. Functional pain — the discomfort patients feel when they actually use their jaw to talk, chew, or yawn — fell by approximately 90 percent. That measure matters because it correlates directly with the activities people care about: eating without discomfort, holding a conversation without flinching, sleeping without jaw spasm waking them up.

The researchers also reported near-elimination of allodynia and hyperalgesia, the heightened pain responses to normally non-painful or mildly painful stimuli. These are signature features of central pain sensitization, and their improvement suggests the cannabinoid combination is doing more than dulling the surface symptom.

Jaw Mobility: From 45.9 to 49.9 Millimeters

Pain relief alone is valuable, but TMD patients also want their jaws back. The trial measured maximum mouth opening — the distance between upper and lower front teeth at the widest the patient can open without pain. Mean opening increased from 45.9 millimeters at the placebo phase to 49.9 millimeters during cannabis treatment, an objective change in physical function.

For context, normal maximum mouth opening in adults is generally above 40 millimeters, with TMD patients often falling well below that benchmark during flares. Adding four millimeters of opening in a chronic population is not trivial; it reflects relaxation in the chewing muscles and reduction in protective guarding around the joint.

Where Cannabis Fits in the Modern TMD Toolkit

The trial does not argue for cannabis as a stand-alone TMD therapy. It argues that a low-dose, balanced THC and CBD protocol may be a useful add-on for patients whose pain is not adequately controlled by physical therapy, splints, and standard medications. The slow up-titration matters: starting at 2 milligrams and adding 2 milligrams per week allows patients to find the lowest effective dose with the fewest side effects.

Two practical takeaways stand out. First, sublingual delivery offered a predictable absorption profile that the study team could measure and replicate. Inhaled cannabis can deliver similar pharmacology but with sharper peaks and a shorter duration that may not match the all-day pain pattern of TMD. Second, the balanced THC and CBD ratio is consistent with a broader 2026 research theme that whole-spectrum cannabinoid pairs often outperform isolates in chronic pain conditions involving inflammation and central sensitization.

How This Lines Up With the Broader 2026 Cannabinoid Pain Research

The TMD trial is one piece of a larger picture. Other studies published in 2026 have found that THC and CBD combinations reduce neuroinflammation, that balanced cannabinoid extracts improve chronic pain outcomes in elderly patients better than THC-dominant products, and that CBD plus chemotherapy can increase tumor cell death in lung cancer models. The throughline is that cannabinoids are increasingly being evaluated for their effects on disease mechanisms — inflammation, immune signaling, central sensitization — rather than only as symptom maskers.

For clinicians, that shift is opening conversations about cannabis as a multimodal pain tool rather than a fringe alternative. For patients, it means more peer-reviewed evidence to discuss with a physician — and more reason to expect that "medical cannabis" will be defined increasingly by specific protocols, doses, and ratios.

What Patients Should Know Before Trying Cannabis for TMD

This single 20-patient trial does not by itself establish standard of care, but it does justify a measured conversation with a qualified clinician. A few practical points apply.

Cannabis is regulated differently in every state and country. Patients should verify legal access and the credentials of any provider recommending products. Sublingual tinctures with verified cannabinoid ratios are easier to dose consistently than flower or vapor. Slow up-titration — exactly what the trial used — minimizes side effects such as drowsiness, dry mouth, and dizziness, especially in patients who have not used cannabis before.

For patients on other medications, drug-drug interactions are worth checking. CBD in particular can affect liver enzymes that metabolize a wide range of drugs. A pharmacist or physician familiar with cannabinoid medicine can help map those interactions.

Where the Research Goes Next

The trial's authors and outside commentators have called for larger, multi-site studies that can replicate the result, extend follow-up, and compare cannabis protocols head-to-head with established TMD therapies. Specific open questions include whether a balanced THC and CBD ratio is optimal, whether higher or lower target doses produce equivalent functional gains, and whether benefits persist after cannabis is tapered.

Funding for these next-stage studies has historically been one of the bottlenecks in cannabis research. With federal Schedule III rescheduling expanding research-friendly pathways for state-licensed medical products in 2026, the operational friction that has slowed cannabis trials may finally be easing. The TMD result is exactly the kind of signal that justifies investment in larger confirmatory work, sitting alongside parallel 2026 work on cannabis and chronic pain in older adults and opioid-replacement signals in post-surgical patients.

Key Takeaways

• A 2026 clinical trial found sublingual balanced THC and CBD extracts reduced average TMD pain scores from 7.35 to 3.50 and cut functional pain by roughly 90 percent.
• Maximum mouth opening improved from 45.9 to 49.9 millimeters, with near-elimination of allodynia and hyperalgesia.
• The protocol used a slow up-titration from 2 milligrams per day to 10 milligrams per day over five weeks, demonstrating that low doses can drive meaningful chronic-pain improvement.
• The findings reinforce a broader 2026 trend toward studying cannabinoids as disease-modifying tools, not just symptom maskers, and call for larger confirmatory trials.

Discussing cannabis as part of a chronic pain plan? Start with a clinician familiar with cannabinoid medicine, and use Budpedia's cannabis dispensary directory to find medical-friendly retailers near you. For the broader picture, our Schedule III rescheduling explainer tracks how the federal change is reshaping access to medical cannabis in 2026.